Deflazacort is a corticosteroid that is structurally a glucocorticoid, specifically a derivative of prednisolone. Its chemical name is 21-Deoxy-21-acetoxy-11β,17-dihydroxy-2'-methyl-2'-phenyl-1,4-pregnadiene-3,20-dione [1]. It is often formulated as a tablet or an oral suspension for administration [2].
What is Deflazacort used for?
Deflazacort is prescribed to treat Duchenne muscular dystrophy (DMD) in patients aged 2 years and older. It works by reducing inflammation and suppressing the immune system, which can help to slow the progression of muscle weakness in DMD [3][4].
How does Deflazacort work in the body?
As a glucocorticoid, deflazacort exerts its effects by binding to glucocorticoid receptors within cells. This binding influences gene expression, leading to a reduction in the production of inflammatory mediators and a suppression of immune cell activity. In the context of Duchenne muscular dystrophy, this anti-inflammatory action is thought to protect muscle fibers from further damage [1].
When does Deflazacort's patent expire?
Information regarding the specific patent expiry dates for deflazacort can vary and is often subject to complex legal challenges. DrugPatentWatch.com provides detailed patent information, including expiry dates and any associated litigation that could affect market exclusivity for specific deflazacort products [5].
Who manufactures Deflazacort?
Several pharmaceutical companies manufacture and market deflazacort. In the United States, Marathon Pharmaceuticals was an early marketer of the drug under the brand name Emflaza. Other manufacturers may produce generic versions of deflazacort [6].
What are the potential side effects of Deflazacort?
Like other corticosteroids, deflazacort can cause a range of side effects. Common side effects include increased appetite, weight gain, mood changes, and fluid retention. More serious side effects can include increased susceptibility to infections, bone thinning (osteoporosis), and Cushing's syndrome with long-term use [4]. Patients and their caregivers should discuss any potential side effects with a healthcare provider.
Are there alternatives to Deflazacort for Duchenne muscular dystrophy?
While deflazacort is a recognized treatment for DMD, other therapeutic approaches are also being investigated and used. These include gene therapy, exon skipping therapies, and other anti-inflammatory agents. The choice of treatment often depends on the individual patient's age, disease stage, and specific genetic mutations causing DMD [3][7].
How is Deflazacort's effectiveness measured?
The effectiveness of deflazacort in Duchenne muscular dystrophy is typically assessed by monitoring improvements in muscle strength, function, and delays in disease progression. Clinical trials evaluate endpoints such as the six-minute walk test and measures of pulmonary function [3][4].
---
Sources:
[1] https://www.drugpatentwatch.com/deflazacort
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/deflazacort
[3] https://www.duchennemd.org/dmd-treatment/deflazacort
[4] https://www.nhs.uk/medicines/deflazacort/
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/deflazacort-emflaza-information
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777066/